Talquetamab - Latest Advances

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.

Journal: The New England journal of medicine

Published: December 08, 2025

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Journal: Leukemia & lymphoma

Published: December 02, 2025

The impact of growth factor utilization on infection risk in patients receiving bispecific monoclonal antibodies.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: November 25, 2025

Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence.

Journal: Expert opinion on biological therapy

Published: November 23, 2025

First case report of talquetamab use in AL amyloidosis.

Journal: Leukemia & lymphoma

Published: October 16, 2025

Correction to "Understanding quality of life under talquetamab: Learning to measure what matters".

Journal: Cancer

Published: October 13, 2025

The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis.

Journal: American journal of hematology

Published: September 27, 2025

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses.

Journal: JCO oncology practice

Published: September 16, 2025

Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary.

Journal: Future oncology (London, England)

Published: September 15, 2025

Dermatological safety of humanized bispecific antibody Talquetamab: skin and nail adverse events related to a novel immunotherapy for multiple myeloma.

Journal: Italian journal of dermatology and venereology

Published: September 10, 2025

Filters

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

The impact of growth factor utilization on infection risk in patients receiving bispecific monoclonal antibodies.

The impact of growth factor utilization on infection risk in patients receiving bispecific monoclonal antibodies.

Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence.

Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence.

First case report of talquetamab use in AL amyloidosis.

First case report of talquetamab use in AL amyloidosis.

Correction to "Understanding quality of life under talquetamab: Learning to measure what matters".

Correction to "Understanding quality of life under talquetamab: Learning to measure what matters".

The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis.

The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis.

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses.

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses.

Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary.

Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary.

Dermatological safety of humanized bispecific antibody Talquetamab: skin and nail adverse events related to a novel immunotherapy for multiple myeloma.

Dermatological safety of humanized bispecific antibody Talquetamab: skin and nail adverse events related to a novel immunotherapy for multiple myeloma.